Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2007

View Archived Issues

Recent patents impart new therapeutic agents for cancer

Recent patents disclose new agents for metabolic disorders

Novel treatment option for respiratory disorders claimed in recent Argenta patent

MEND-CABG II study of MC-1 recommended to continue

CollaGenex discontinues 40 mg cohort in phase II acne study of incyclinide

COSTAR II study fails to meet endpoints

New data indicate Homspera may demonstrate adjuvant capabilities

TorreyPines to sell assets for treating autoimmune diseases to CalciMedica

New bioavailability data for BEMA Fentanyl

Australian TGA accepts Solbec's development plan for Coramsine

Interim three-month data for ISA-247 kidney transplant trial

Preliminary phase IIa data indicate utility of AT-1001 in celiac disease

New data on NX-1207 show sustained symptomatic improvement in BPH

AEterna Zentaris updates clinical progress

European CHMP recommends approval of Siklos

TRPV1 channel as a novel drug target in ocular disorders

Recent clinical data on intravitreal bevacizumab in ophthalmological conditions

Calcineurin inhibitor-free regimen with CP-690550 effective in renal transplantation

Studies show efficacy of lamotrigine in epilepsy

Abatacept associated with reduced flare incidence in juvenile idiopathic arthritis

Vision maintained with combretastatin A-4 in choroidal neovascularization patients

SRI International regains rights to tirapazamine from sanofi-aventis

Omrix seeks Swedish approval for HBIG product

New licensing agreement for NM-702 for arteriosclerosis obliterans

AEterna Zentaris regains rights for cetrorelix from Solvay

Fabre-Kramer amends NDA for gepirone ER in major depressive disorder

Adverse event reported in phase II anemia trial of FG-2216

PAC-113 active in the treatment of oral Candida infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...